Straits Times Index
3,284.74 -3.01 (-0.09%) Nikkei
37,780.35 +151.87 (+0.40%) Hang Seng
17,573.91 +289.37 (+1.67%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,391.43 +74.28 (+0.12%) CMC Crypto 200
1,391.93 +9.36 (+0.68%)
KKR & Co. Inc. (0Z1W.L)
| Previous close | 96.56 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,380 |
| Market cap | 809.138M |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | 4.63 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider Monkey15 Best Cheap Stocks To Buy For 2024
In this article, we will take a look at the 15 best cheap stocks to buy for 2024. If you’d like to skip our overview of investing and some recent financial news, then please take a look at the 5 Best Cheap Stocks To Buy For 2024. While the Federal Reserve may take its time […]
- Business Wire
KKR to Acquire $1.64 Billion Student Housing Portfolio from BREIT
NEW YORK, April 25, 2024--KKR and Blackstone Real Estate Income Trust, Inc. ("BREIT") today announced a definitive agreement for funds managed by KKR to acquire a portfolio of 19 purpose-built student housing properties from BREIT for approximately $1.64 billion.
- Business Wire
KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
STOCKHOLM & LONDON, April 23, 2024--Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
